There are a lot of reasons why oncologists aren't exactly brimming with excitement at the idea of getting their hands on Eli Lilly's lung cancer drug necitumumab.
It's happened: Eli Lilly & Co. and Boehringer Ingelheim have rolled out their biosimilar version of Lantus in its first major market. The U.K. launch follows some smaller rollouts in Eastern Europe--and it's the next move in a planned worldwide assault on the Sanofi diabetes stalwart.
Eli Lilly has fought tooth and nail to protect a patent for its blockbuster cancer drug Alimta, chalking up some victories in the U.S. despite setbacks overseas. Now the company is celebrating a big win as a federal court ruled in its favor, granting Lilly 5 more years of Alimta exclusivity in the U.S.
Eli Lilly has fought tooth and nail to protect a patent for its blockbuster cancer drug Alimta, chalking up some victories in the U.S. despite setbacks overseas. Now the company is celebrating a big win as a federal court ruled in its favor, barring copycat versions of the drug and granting Lilly 5 more years of U.S. exclusivity for Alimta.
The first half of the year has provided a good ride for Big Pharma and its investors with indices up in the U.S. and Europe. Even Japanese drugmakers avoided the side effects of China's stock market meltdown and saw values rise 23%. But, of course, averages come from the highs and the lows and some players have actually seen share price declines during this bull market.
Eli Lilly has been making its fair share of courtroom appearances lately, battling claims over withdrawal symptoms linked to its blockbuster antidepressant in the U.S. and defending a patent for a lung cancer drug in Europe. In its latest legal saga, the drugmaker is going head-to-head with a woman who claims that Lilly stole her idea for a tool that helps patients' remember to take their meds.
Eli Lilly is staking its future on a pair of high-stakes Phase III programs, shying away from any big biotech buyouts as sticker prices continue to soar.
Industry watchers have pointed to a slowdown in pharma's emerging markets growth as a worrying sign for companies that have been heavily targeting developing nations while the U.S. and European markets stagnate. But just how slow has the growth become?
U.S.-based Abbott Laboratories is among a number of companies that hope to leverage acquisitions in Russia into exports, with other players such as India's Lupin among other potential firms to look to ship wider abroad.
Eli Lilly has nabbed a win in the first U.S. trial over claims of withdrawal symptoms linked to its blockbuster antidepressant, Cymbalta. With more trials on the way--and thousands of cases alleging that the drugmaker soft-pedaled on the drug's withdrawal symptoms--the early victory could score the Indianapolis drugmaker some leverage.